Thonningine A



Compound IDCDAMM00886
Common nameThonningine A
IUPAC name6-(1,3-benzodioxol-5-yl)-5-hydroxy-4,9-dimethoxy-2-prop-1-en-2-ylfuro[3,2-g]chromen-7-one
Molecular formulaC23H18O8

Experimental data

Retention time0.27
Adduct[M+H]+
Actual mz423.106
Theoretical mz423.107
Error3.02
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.3423

Identifiers and class information

Inchi keyDHHUFQCTMOFVTD-UHFFFAOYSA-N
SmilesO=C1OC=2C(OC)=C3OC(=CC3=C(OC)C2C(O)=C1C=4C=CC=5OCOC5C4)C(=C)C
SuperclassPhenylpropanoids and polyketides
ClassCoumarins and derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)0
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)5
Number of reactive functional groups (#rtvFG)1
Predicted central nervous system activity (CNS)0
Molecular weight (mol_MW)422.39
Computed dipole moment(dipole)7.89
Total solvent accessible surface area (SASA)640.327
Hydrophobic component of SASA (FOSA)342.612
Hydrophilic component of SASA (FISA)79.419
Pie component of the SASA (PISA)218.296
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1177.68
Number of hydrogen bond donors (donorHB)1
Number of hydrogen bond acceptors (accptHB)6.75
Free energy of solvation of dipole (dip^2/V)0.0528633
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0105415
Globularity descriptor (glob)0.842265
Predicted polarizability in cubic angstroms (QPpolrz)39.851
Predicted hexadecane/gas partition coefficient (QPlogPC16)11.488
Predicted octanol/gas partition coefficient (QPlogPoct)18.706
Predicted water/gas partition coefficient (QPlogPw)10.296
Predicted octanol/water partition coefficient (QPlogPo/w)3.565
Predicted aqueous solubility (QPlogS)-4.655
Conformation-independent predicted aqueous solubility (CIQPlogS)-6.352
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.125
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)1748.9
Predicted brain/blood partition coefficient (QPlogBB)-0.484
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)905.212
Predicted skin permeability, log Kp (QPlogKp)-1.734
PM3 calculated ionization potential (IP(ev))8.758
PM3 calculated electron affinity (EA(eV))1.14
Number of likely metabolic reactions (#metab)5
Prediction of binding to human serum albumin (QPlogKhsa)0.291
Predicted qualitative human oral absorption (HumanOralAbsorption)3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)100
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)95.924
Number of nitrogen and oxygen atoms (#NandO)8
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
Q02750MAP2K1Dual specificity mitogen-activated protein kinase kinase 1T99057SwissTargetPrediction
P49759CLK1Dual specificty protein kinase CLK1T46685SEA
Q9Y463DYRK1BDual specificity tyrosine-phosphorylation-regulated kinase 1BT82720SEA
Q9NWZ3IRAK4Interleukin-1 receptor-associated kinase 4T55398SwissTargetPrediction
Q9HAZ1CLK4Dual specificity protein kinase CLK4T98225SEA
P25101EDNRAEndothelin receptor ET-AT23499SEA
P49760CLK2Dual specificity protein kinase CLK2T73725SEA
P49761CLK3Dual specificity protein kinase CLK3T21585SEA
P24530EDNRBEndothelin receptor ET-BT92828SEA
P35557GCKHexokinase type IVT87166SwissTargetPrediction
P19438TNFRSF1ATumor necrosis factor receptor R1T86552SEA
H3BPQ1TCF4Transcription factor 7-like 2T54646SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T99057DI0262Metastatic tumour[ICD-11: 2D50-2E2Z]Q02750MAP2K1
T99057DI0336Phakomatoses/hamartoneoplastic syndrome[ICD-11: LD2D]Q02750MAP2K1
T55398DI0039Atopic eczema[ICD-11: EA80]Q9NWZ3IRAK4
T55398DI0109Cutaneous lupus erythematosus[ICD-11: EB50-EB5Z]Q9NWZ3IRAK4
T55398DI0241Lymphoma[ICD-11: 2A80-2A86]Q9NWZ3IRAK4
T55398DI0339Postoperative inflammation[ICD-11: 1A00-CA43]Q9NWZ3IRAK4
T55398DI0351Psoriasis[ICD-11: EA90]Q9NWZ3IRAK4
T55398DI0366Rheumatoid arthritis[ICD-11: FA20]Q9NWZ3IRAK4
T23499DI0070Cardiovascular disease[ICD-11: BA00-BE2Z]P25101EDNRA
T23499DI0356Pulmonary hypertension[ICD-11: BB01]P25101EDNRA
T23499DI0425Urinary system clinical symptom[ICD-11: MF8Y]P25101EDNRA
T92828DI0070Cardiovascular disease[ICD-11: BA00-BE2Z]P24530EDNRB
T92828DI0356Pulmonary hypertension[ICD-11: BB01]P24530EDNRB
T87166DI0009Acute diabete complication[ICD-11: 5A2Y]P35557GCK
T87166DI0120Diabetes mellitus[ICD-11: 5A10]P35557GCK
T87166DI0308Obesity[ICD-11: 5B80-5B81]P35557GCK
T87166DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P35557GCK
T86552DI0060Brain cancer[ICD-11: 2A00]P19438TNFRSF1A
T86552DI0321Ovarian cancer[ICD-11: 2C73]P19438TNFRSF1A

Copyright © 2025